Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

This article compares two passive health care ETFs—XLV (State Street) and VHT (Vanguard)—examining their relative performance and structural differences. The analysis highlights a classic trade-off between concentration and diversification: XLV's 60-stock portfolio has outperformed VHT's 423 holdings over a five-year horizon, suggesting that focused exposure to larger health care positions generated stronger long-term alpha. Conversely, VHT demonstrated superior one-year returns, indicating shorter-term momentum favored broader diversification.

The performance differential reflects underlying portfolio construction philosophy rather than active management skill, as both are passive vehicles tracking health care indices. XLV's concentration amplifies exposure to dominant names like pharmaceutical and medical device leaders, creating higher beta relative to the health care sector. This structure benefits during periods when mega-cap health care outperforms mid- and small-cap peers, but introduces concentration risk during sector rotations or individual name weakness.

VHT's broader mandate reduces single-name exposure and provides more granular sector coverage across pharmaceuticals, medical devices, biotech, and health care services. The one-year outperformance may signal a recent rotation favoring diversified health care exposure over concentrated mega-cap positioning. Neither fund choice materially impacts systematic market correlation; both track the same health care sector fundamentals.

Sector implication: Health care ETF selection is a tactical decision within a given sector allocation rather than a market-level catalyst. Ongoing performance divergence will depend on health care sub-sector rotation, regulatory developments (drug pricing, FDA approvals), and relative valuation dynamics between large-cap and diversified health care holdings.